Bladder Cancer

Epidemiology & Risk Factors - Bladder's Bad Bets

• Incidence: Common; Men > Women (~3:1). Peak: 60-70 yrs.
• Higher in industrialized nations.
• Major Risk Factors:

  • ⭐ Smoking: Single largest risk factor, ~50% cases. Risk ↑ with duration/intensity.

  • Occupational: Aromatic amines (benzidine, β-naphthylamine) in dye, rubber, textile, paint industries.
  • Chronic Bladder Irritation: Schistosomiasis (↑ Squamous Cell Carcinoma risk), chronic UTIs, stones.
  • Drugs: Cyclophosphamide, phenacetin.
  • Pelvic Irradiation.
  • Genetic: Lynch syndrome, NAT & GST polymorphisms.
  • Aristolochic acid (herbal remedies). 📌 Mnemonic (Chemicals): "Pee SAC" (Phenacetin, Smoking, Aniline dyes, Cyclophosphamide). oka

Pathology & Staging - Cancer's ID Card

• Histological Types:
  • Urothelial (Transitional Cell) Carcinoma (TCC): >90% of cases.
    • Papillary: Most common, often low grade, better prognosis.
    • Flat (Carcinoma In Situ - CIS): High grade, aggressive potential if untreated.
  • Squamous Cell Carcinoma (SCC): ~5% (associated with chronic irritation, Schistosomiasis).
  • Adenocarcinoma: <2% (often from urachal remnant or bladder exstrophy).

⭐ Urothelial (Transitional Cell) Carcinoma is the most common type (>90%).

• TNM Staging (AJCC 8th Ed. Overview): Defines tumor extent, nodal spread, and metastasis.
  • T (Primary Tumor): Depth of bladder wall invasion.
    • Non-Muscle Invasive Bladder Cancer (NMIBC): Ta (non-invasive papillary), Tis (CIS), T1 (invades lamina propria).
    • Muscle Invasive Bladder Cancer (MIBC): T2 (invades muscularis propria), T3 (invades perivesical fat/tissue), T4 (invades adjacent organs e.g., prostate, uterus, pelvic wall).
  • N (Regional Lymph Nodes): N0 (no lymph node spread) to N3 (spread to common iliac nodes).
  • M (Distant Metastasis): M0 (no distant spread) or M1 (distant sites e.g., lung, liver, bone).

Clinical Features & Diagnosis - Spotting the Trouble

⭐ Painless gross hematuria is the classic presenting symptom, seen in 80-90% of patients.

• Key Symptoms:
  • Painless visible hematuria (most frequent).
  • Irritative voiding: Dysuria, frequency, urgency (esp. with CIS).
  • Advanced: Pelvic/flank pain (obstruction), constitutional symptoms.
• Diagnostic Steps:
  1. Urine Evaluation:
     • Urinalysis, Cytology (High Sp for High-Grade/CIS).
     • Tumor Markers (NMP22, BTA): Adjunctive.
  2. Cystoscopy & TURBT:
     • Gold standard for diagnosis & initial staging (T-stage, grade).
     • Allows biopsy/resection.
     • 📌 Bimanual Exam Under Anesthesia (BEUA) during TURBT assesses local invasion.
  3. Imaging for Staging:
     • CT Urography (CTU): Evaluates entire urothelium; stages local/nodal/distant disease.
     • MRI: Detailed local staging.
     • Chest/Bone Scan: Metastatic workup for Muscle-Invasive Bladder Cancer (MIBC).

Management Principles - Battling the Bulge

• Goal: Cure, Bladder Preservation, QoL.
• NMIBC (Ta, T1, CIS):
  • Transurethral Resection of Bladder Tumor (TURBT) is diagnostic & therapeutic.
  • Adjuvant Intravesical Therapy:
    • Low Risk: Single Mitomycin C dose.
    • Intermediate Risk: Mitomycin C or BCG.
    • High Risk: BCG (Bacillus Calmette-Guérin).

⭐ Intravesical BCG is the mainstay for high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) after TURBT.

• MIBC (≥T2):
  • Neoadjuvant Chemotherapy (NAC) with Cisplatin (if fit) improves survival.
  • Radical Cystectomy (RC) + Pelvic Lymph Node Dissection (PLND) = Gold Standard.
  • Urinary Diversion: Ileal conduit, Orthotopic neobladder.
  • Bladder Preservation: Trimodal Therapy (TURBT + Chemo + RT) in select patients.
• Metastatic (M1): Systemic Chemo, Immunotherapy.

High-Yield Points - ⚡ Biggest Takeaways

• Transitional Cell Carcinoma (TCC) is the most common type (>90%).
• Painless gross hematuria is the classic presenting symptom.
• Cigarette smoking is the single most important risk factor. Others: aromatic amines, cyclophosphamide.
• Cystoscopy with biopsy is the gold standard for diagnosis and staging.
• NMIBC (Non-Muscle Invasive): TURBT + intravesical BCG (most effective for high-risk).
• MIBC (Muscle Invasive): Radical cystectomy ± neoadjuvant chemotherapy (improves survival).